Abiopharma

🔍 FOEHR MATTHEW W (Executive)

Company: Viking Therapeutics, Inc. (VKTX)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 16,000 shares of Common Stock, par value $0.00001 per share at $3.33 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: false | shares_owned_after: 148,036.00 | transaction_form_type: 4
• Sold 16,000 shares of Common Stock, par value $0.00001 per share at $35.1059 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: false | shares_owned_after: 132,036.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 3,150 shares of Common Stock, par value $0.00001 per share (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 135,186.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 16,000 shares of Stock Option (Right to Buy) at $3.33 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2026-01-04 | Exercise: 2017-01-04 | equity_swap_involved: false | transaction_form_type: 4
• Acquired 20,400 shares of Stock Option (Right to Buy) at $35.42 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | Exercise: 2027-01-02 | equity_swap_involved: false | shares_owned_after: 20,400.00 | transaction_form_type: 4

Footnotes:

• F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.